Skip to content

A prospective and observational clinical trial of the change of cardiac function and electrocardiology in lymphoma and multiple myeloma patients

A prospective and observational clinical trial of the change of cardiac function and electrocardiology in lymphoma and multiple myeloma patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063442
Enrollment
Unknown
Registered
2022-09-06
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma and multiple myeloma

Interventions

Case series:None

Sponsors

The Forth Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with lymphoma and multiple myeloma diagnosed for the first time: (1) Lymphoma patients have a clear pathological diagnosis, meet the "Chinese Lymphoma Diagnosis and Treatment Guidelines" lymphoma pathological diagnosis standards, and have a clear imaging stage; (2) Patients with multiple myeloma are diagnosed in line with the diagnostic criteria for multiple myeloma in the "Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma" and have a clear staging; 2. Prepare to receive systematic treatment for the primary disease; 3. The expected survival period is more than half a year; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Aged < 18 years; 2. Serious and uncontrolled underlying diseases, so that patients can only receive palliative symptomatic treatment; 3. Uncontrolled cardiovascular disease.

Design outcomes

Primary

MeasureTime frame
haemoglobin;white blood cell;platelet;neutrophils;lymphocyte;basophils;eosinophils;sodium;potassium;chlorine;calcium;total cholesterol;triglycerides;high-density lipoprotein;LDL;Alanine aminotransferase;Aspartate aminotransferase;albumin;Total bilirubin;Direct bilirubin;Indirect bilirubin;alkaline phosphatase;creatinine;urea;glucose;Glycosylated hemoglobin;BNP;creatine kinase;Creatine kinase isoenzyme;Troponin T;Troponin I;Heart rate variability;QT interval discreteness;24 h blood pressure average;Blood pressure stress value;Rate of decrease in blood pressure at night;Range of blood pressure fluctuations;LVEF, Left ventricular ejection fraction;FS, Left Ventricular Fraction Shortening;PWV, pulse wave velocity;GLS, left ventricular global strain;GCS, global circumferential strain;GRS, global radial strain;LVESV, left ventricular end systolic volume;LVEDV, left ventricular end diastolic volume;Ea, Early diastolic peak velocity of mitral annulus root;Aa, Peak velocity of mitral annular root in late diastole;Sa, systolic mitral annular velocities;E peak;A peak;E/A;

Countries

China

Contacts

Public ContactLiu haisheng

The Forth Hospital of Hebei Medical University

liuhs78299@163.com+86 13933078299

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026